Recce Pharmaceuticals Enters Agreement with Path BioAnalytics to Test RECCE® Compounds in Expanded SARS-CoV-2 Program

    NEXT STORY
    TRACON Pharmaceuticals Announces Filing of Protocol for ENVASARC Pivotal Trial with the FDA
    PREV STORY
    Results of Annual General Meeting
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Constellation Pharmaceuticals Announces Second-Quarter 2020 Financial Results, Provides Regulatory Update

    author_avatar
    NASDAQ Market News

    Incyte and Zai Lab Announce Collaboration and License Agreement for INCMGA0012 in Greater China

    author_avatar
    NASDAQ Market News

    CohBar’s Chief Operating Officer Jon Stern Plans to Step Down from Management Role

    author_avatar
    NASDAQ Market News